Upgrade to SI Premium - Free Trial

Regeneron Pharma (REGN) PT Raised to $400 at Barclays Following 1Q Report; 'Initial Strength of the Dupixent Launch'

May 5, 2017 2:46 PM
Barclays raised its price target on Regeneron Pharma (NASDAQ: REGN) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change FDA

Next Articles